MicroSectors FANG and Innovation 3X Leveraged ETN vs Nuwellis Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $27.66, while Nuwellis Inc trades at $2.9 (market cap $1.10M). The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| FNGU | NUWE | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $36.15 | $558.26 |
52-Week Low | $13.73 | $2.80 |
Market Cap | — | $1.10M |
Enterprise Value | — | -$709.83K |
Signals from Pluang's Aura AI — not financial advice
FNGU, a leveraged ETN tracking the FANG+ Index, trades at $28.79, down 0.38% on the day. Technical indicators show mixed signals with moving averages bullish but oscillators bearish, including overbought RSI readings above 80. Recent performance highlights extreme volatility, with a documented 16% single-session drop on June 5, 2026, illustrating the amplified risks of its 3x leverage structure.
The outlook for FNGU is highly speculative, driven entirely by momentum in its underlying tech stocks rather than traditional fundamentals. Investment opportunity exists for aggressive traders betting on continued tech sector strength, but risks are severe, including decay from daily resets and catastrophic losses during market downturns, as recent news demonstrates.
Nuwellis (NUWE) trades at $2.85, down 11.49% in the last session, reflecting ongoing financial challenges despite recent strategic initiatives. The stock shows a bearish technical outlook with negative cash flow and widening losses, though it maintains a high gross margin of 65.47%. Recent corporate actions include a 35:1 reverse stock split in June 2026 and a $6 million public offering to fund operations.
The outlook remains challenging with significant losses and negative profitability metrics, though new CEO leadership and patent developments offer potential catalysts. Investment opportunities exist in the company's niche pediatric cardiorenal market, while risks include cash burn, execution challenges, and competitive pressures in medical technology.
Trailing returns across standard periods
Latest headlines on both assets
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →